Holen Sie sich die Stockscreener-App
0.7787
2.66%
-0.0213
Elutia Inc Aktie (ELUT) Neueste Nachrichten
Elutia Receives $8 Million Payment From Boston Scientific Company Now Fully Funded Into 2029 - TradingView
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
Elutia receives $8 million escrow from Boston Scientific sale - Investing.com India
The buyer releases $8 million held back from Elutia's sale. Elutia believes funding extends into 2029. - Stock Titan
Elutia Receives $8 Million Payment from Boston Scientific; Company Now Fully Funded into 2029 - GlobeNewswire
Elutia, Inc. ELUT Stock Forecast & Price Target - Yahoo! Finance Canada
ELUT Q2 2026 Earnings: Wider-Than-Expected Loss Draws Muted Market ResponseEarnings Whisper Number - dars.gov.et
Elutia CFO Matthew Ferguson Executes 12,500 Options and Forfeits Shares in Insider Deal - kalkinemedia.com
ELUT: Drug-eluting biomatrix targets surgical infections, with strong demand and full funding to launch - TradingView
Elutia at H.C. Wainwright conference: capital, data and launch path By Investing.com - Investing.com India
Elutia at H.C. Wainwright conference: capital, data and launch path - Investing.com
Elutia to Present at the H.C. Wainwright 28th Annual Global Investment Conference on September 15th - marketscreener.com
Elutia will discuss how to address infections after reconstructive surgery - Stock Titan
Elutia Inc. (NASDAQ: ELUT) Share Price, ELUT Stock News, ELUT Share Price & Updates - kalkine.com.au
Elutia to Participate in the Lake Street Capital Markets - GlobeNewswire
Post-surgical infections will be discussed at Elutia's upcoming talks - Stock Titan
Elutia (ELUT) Holds Steady at $0.88 as Shares Consolidate Between Support and ResistanceOpening Range Breakout - careplusvn.com
Elutia Inc. Earnings Call Highlights Funding, NXT Outlook - TipRanks
Elutia (ELUT) Move: Moves 2.32% Lower to $0.90; Price Levels: Traders Can Monitor the $0.85-$0.95 Range under the Current SnapshotSwing Entry Signals - vinanet.vn
Elutia Completes SimpliDerm® Sale on Schedule, Adds $8 Million in Cash to Fund NXT-41x Through Full Commercial Launch - Sahm
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Gain Therapeutics (GANX), Summit Therapeutics (SMMT) and Elutia (ELUT) - The Globe and Mail
Cellution Biologics Acquires SimpliDerm From Elutia for Up to $11 Million - citybiz
ELUT Looks 5.6% Overvalued on GF Value™ - GuruFocus
Cellution Biologics Completes Acquisition of SimpliDerm® from Elutia Inc. - The Manila Times
Elutia Flat on Sale to Cellution - Baystreet.ca
Elutia sells SimpliDerm business for up to $11 million - Investing.com
Elutia sells SimpliDerm business for up to $11 million By Investing.com - Investing.com India
Elutia gets $8 million at closing as FDA clearance is expected in 2027 - Stock Titan
SILVERARC CAPITAL MANAGEMENT, LLC Trims Elutia Inc (ELUT) Stake -- Shares Look 11% Overvalued on GF Value - GuruFocus
Cellution Biologics Llc completed the acquisition of SimpliDerm human acellular dermal matrix business of Elutia Inc. for $11 million. - marketscreener.com
Elutia (ELUT) Q2 2026 Earnings: Wider-Than-Expected Loss as Shares Advance 1.49%Earnings Outlook Update - vinanet.vn
Elutia Inc (ELUT) Stock News Today - TradingKey
Elutia Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:ELUT) 2026-08-16 - Seeking Alpha
Downgrade: What You Need To Know About The Latest Elutia Inc. (NASDAQ:ELUT) Forecasts - simplywall.st
Elutia secures $26M to launch NXT-41x, targetin... - Pluang
Elutia Secures Up to $26 Million to Fund NXT-41x Through Commercial Launch; Reports Second Quarter 2026 Results - Sahm
Elutia Q2 2026 slides: $26M capital raise funds NXT41x launch - Investing.com Australia
Elutia Inc. (ELUT): SilverArc Capital reports 4.9% stake in Class A shares - Stock Titan
Elutia Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Elutia Inc (ELUT) (Q2 2026) Earnings Call Highlights: Strategic - GuruFocus
Elutia Inc (ELUT) (Q2 2026) Earnings Call Highlights: Strategic Pivot to NXT41X Drives Strong ... By GuruFocus - Investing.com Canada
ELUT Looks 2.2% Undervalued on GF Value™ Amid Challenging Sales and Cash Flow - GuruFocus
Earnings call transcript: Elutia Q2 2026 revenue miss offset by margin gains - Investing.com Nigeria
ELUT: Q2 delivered improved margins, strong funding, and high surgeon demand for NXT-41x - TradingView
Elutia secures $26M in capital, expects FDA decision on NXT-41 - Investing.com Australia
Elutia Q2 2026 Earnings Call Transcript - Benzinga
ELUT: Improved margins, strong funding, and high surgeon demand set up NXT-41x for 2028 launch - TradingView
Elutia Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Elutia Inc. Secures $15 Million Loan Financing from Avenue Capital Group to Fund NXT-41X Launch in $1.5 Billion Plastic and Reconstructive Surgery Market - marketscreener.com
Elutia secures $15 million financing for product development By Investing.com - Investing.com Nigeria
Elutia Inc. (ELUT) Stock Falls on Q2 2026 Earnings - Quiver Quantitative
Is Elutia Inc (ELUT) Positioned for Growth After Q2 Earnings? EPS at -$0.15, Revenue at $2.90M -- GF Score: 34/100 - GuruFocus
Elutia Secures $15 Million Loan Financing From Avenue Capital Group - TradingView
Elutia secures $15 million financing for product development - Investing.com
0.26%
0.38%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):